These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. [Therapy of hypertension. Also pulse pressure must be reduced]. MMW Fortschr Med; 2003 Sep; 145(37):65. PubMed ID: 14584451 [No Abstract] [Full Text] [Related]
23. New clinical concepts after the ONTARGET trial. Ruilope LM; Segura J; Zamorano JL Expert Rev Cardiovasc Ther; 2011 Jun; 9(6):685-9. PubMed ID: 21714599 [TBL] [Abstract][Full Text] [Related]
24. [In the framework of the 72nd Annual Meeting of the DKG (German CardiologySociety) in Mannheim presented: Ontarget-the until now largest study program on cardiovascular prevention in patients with hypertension]. MMW Fortschr Med; 2006 Jun; 148(26):50-1. PubMed ID: 16875381 [No Abstract] [Full Text] [Related]
25. Prevention of stroke in patients with hypertension. Dahlöf B Am J Cardiol; 2007 Aug; 100(3A):17J-24J. PubMed ID: 17666193 [TBL] [Abstract][Full Text] [Related]
26. ONTARGET, TRANSCEND and PROFESS--clarifying, confusing or misleading? Oparil S; Kjeldsen SE; Hedner T; Narkiewicz K Blood Press; 2009; 18(1-2):4-6. PubMed ID: 19191085 [No Abstract] [Full Text] [Related]
27. Telmisartan vs losartan plus hydrochlorothiazide in the treatment of mild-to-moderate essential hypertension--a randomised ABPM study. Neutel JM; Kolloch RE; Plouin PF; Meinicke TW; Schumacher H; J Hum Hypertens; 2003 Aug; 17(8):569-75. PubMed ID: 12874615 [TBL] [Abstract][Full Text] [Related]
28. [The effect of the new angiotensin-converting enzyme inhibitor moexipril on the circadian rhythms of arterial pressure in hypertension patients]. Ol'binskaia LI; Andrushchishina TB Ter Arkh; 1997; 69(3):58-61. PubMed ID: 9229835 [TBL] [Abstract][Full Text] [Related]
29. ONTARGET programme of cardio- and vascular protection - first results are imminent. Cardiovasc J Afr; 2008; 19(1):46-8. PubMed ID: 18320089 [No Abstract] [Full Text] [Related]
30. AT1 receptor antagonist telmisartan administered peripherally inhibits central responses to angiotensin II in conscious rats. Gohlke P; Weiss S; Jansen A; Wienen W; Stangier J; Rascher W; Culman J; Unger T J Pharmacol Exp Ther; 2001 Jul; 298(1):62-70. PubMed ID: 11408526 [TBL] [Abstract][Full Text] [Related]
31. Results of a comparative, phase III, 12-week, multicenter, prospective, randomized, double-blind assessment of the efficacy and tolerability of a fixed-dose combination of telmisartan and amlodipine versus amlodipine monotherapy in Indian adults with stage II hypertension. Sharma A; Bagchi A; Kinagi SB; Sharma YK; Baliga VP; Bollmall C Clin Ther; 2007 Dec; 29(12):2667-76. PubMed ID: 18201582 [TBL] [Abstract][Full Text] [Related]
32. Telmisartan vs. enalapril in type 2 diabetes. Parving HH; Hovind P; Rossing P N Engl J Med; 2005 Feb; 352(8):835-6; author reply 835-6. PubMed ID: 15736292 [No Abstract] [Full Text] [Related]
33. [Therapy of hypertension with expanded outlook. Constant pressure decline and organ protection]. MMW Fortschr Med; 2007 Dec; 149(49-50):52-3. PubMed ID: 18236984 [No Abstract] [Full Text] [Related]
36. Evaluation of fixed dose combination (FDC) of telmisartan+ramipril usage in patients with micro-albuminuria and persistent hypertension: A TRIUMPH study. Sharma A; Baliga V; J Indian Med Assoc; 2008 Mar; 106(3):191-4, 196. PubMed ID: 18712142 [TBL] [Abstract][Full Text] [Related]
37. Possible beneficial effect of telmisartan on glycemic control in diabetic subjects. Honjo S; Nichi Y; Wada Y; Hamamoto Y; Koshiyama H Diabetes Care; 2005 Feb; 28(2):498. PubMed ID: 15677828 [No Abstract] [Full Text] [Related]
38. ONTARGET to provide new treatment strategies for high-risk cardiovascular patients. Understanding the role of PPARgamma in blood pressure control. Cardiovasc J Afr; 2007; 18(3):186-7. PubMed ID: 17612754 [No Abstract] [Full Text] [Related]